BioSpace News Archive

Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Telesis Bio Inc., a leader in automated multi-omic and synthetic biology solutions, reported financial results for the first quarter of 2023.

IntelGenx Technologies Corp. reported financial results for the first quarter ended March 31, 2023.

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the first quarter ended March 31, 2023 and provided recent corporate and clinical updates.

Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced the publication of the results of its US multicenter pilot trial in JAMA Network Open.

Inotiv, Inc., a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced financial results for the three months and six months ended March 31, 2023.

Journey Medical Corporation announced that it has postponed the release of its first fiscal quarter financial results and conference call, previously scheduled for Thursday, May 11, 2023, to provide additional time to complete the finalization of its financial statements.

Rezolute, Inc. announced its financial results for the third quarter of fiscal 2023 ended March 31, 2023.

ProKidney Corp., a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, announced financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments.